End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
78 TWD | -0.76% | +1.17% | -2.99% |
14/03 | TTY Biopharm Company Limited Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
08/03 | TTY Biopharm Company Limited Announces Change of CFO and Financial Officer | CI |
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-2.99% | 603M | - | ||
+32.36% | 698B | C+ | ||
+26.51% | 568B | B | ||
-4.40% | 358B | C+ | ||
+19.46% | 328B | B- | ||
+3.50% | 283B | C+ | ||
+16.34% | 238B | B+ | ||
+6.68% | 203B | B- | ||
-9.08% | 198B | A+ | ||
+8.62% | 165B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 4105 Stock
- Ratings TTY Biopharm Company Limited